Microfluidics Device Captures and Isolates Slow Growing Gut Bacteria
|
By LabMedica International staff writers Posted on 15 Jul 2014 |

Image: Glass SlipChip for growing microbes, shown next to a US quarter dollar coin (left); fluorescent in situ hybridization image of the target organism (right, top); transmission electron microscopy image of a single cell of the target organism (right, bottom) (Photo courtesy of the California Institute of Technology).
Microbiologists have used a novel "lab-on-a-chip" approach to isolate and cultivate fastidious, slow growing bacteria from the human digestive tract.
The majority of microbes that comprises the human gut biome have not been cultured, due in part to the difficulties of both identifying proper growth conditions and characterizing and isolating each species.
Investigators at the California Institute of Technology (Pasadena, USA) developed a microfluidics-based, genetically targeted approach to overcome these problems. Their "SlipChip" device was constructed from two glass slides, each the size of a credit card, that were etched with tiny grooves that became channels when the grooved surfaces were stacked atop one another. When a sample, such as a mixed assortment of bacterial species from a colonoscopy biopsy, was applied to the device, the interconnected channels of the top chip turned the channels into individual wells, with each well ideally holding a single microbe. Once sequestered in an isolated well, each individual bacterium was able to divide and grow without having to compete for resources with other types of faster-growing microbes.
The beauty of the system was that each well could be divided into two compartments. One compartment was used for DNA sequencing and mapping studies while the other maintained a living example of the microbe for further culture and study.
The investigators validated this approach by cultivating a bacterium from a human cecal biopsy. Genetic mapping of the organism showed that it was a representative of a previously unidentified genus of the Ruminococcaceae family and that its genetic signature was listed among the high-priority group of the [US] National Institutes of Health's Human Microbiome Project’s "Most Wanted" list.
"Although a genomic sequence of the new organism is a useful tool, further studies are needed to learn how this species of microbe is involved in human health," said senior author Dr. Rustem Ismagilov, professor of chemistry and chemical engineering at the California Institute of Technology.
The study was published in the June 25, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
California Institute of Technology
The majority of microbes that comprises the human gut biome have not been cultured, due in part to the difficulties of both identifying proper growth conditions and characterizing and isolating each species.
Investigators at the California Institute of Technology (Pasadena, USA) developed a microfluidics-based, genetically targeted approach to overcome these problems. Their "SlipChip" device was constructed from two glass slides, each the size of a credit card, that were etched with tiny grooves that became channels when the grooved surfaces were stacked atop one another. When a sample, such as a mixed assortment of bacterial species from a colonoscopy biopsy, was applied to the device, the interconnected channels of the top chip turned the channels into individual wells, with each well ideally holding a single microbe. Once sequestered in an isolated well, each individual bacterium was able to divide and grow without having to compete for resources with other types of faster-growing microbes.
The beauty of the system was that each well could be divided into two compartments. One compartment was used for DNA sequencing and mapping studies while the other maintained a living example of the microbe for further culture and study.
The investigators validated this approach by cultivating a bacterium from a human cecal biopsy. Genetic mapping of the organism showed that it was a representative of a previously unidentified genus of the Ruminococcaceae family and that its genetic signature was listed among the high-priority group of the [US] National Institutes of Health's Human Microbiome Project’s "Most Wanted" list.
"Although a genomic sequence of the new organism is a useful tool, further studies are needed to learn how this species of microbe is involved in human health," said senior author Dr. Rustem Ismagilov, professor of chemistry and chemical engineering at the California Institute of Technology.
The study was published in the June 25, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
California Institute of Technology
Latest Microbiology News
- Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
- Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
- Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
- Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
- Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
- Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
- Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read moreMolecular Diagnostics
view channel
Blood-Based Small RNA Assay Predicts Survival After Lung Cancer Treatment
Locally advanced, non-resectable stage III lung cancer includes patients whose outcomes can vary substantially after curative-intent treatment. Progression-free and overall survival are therefore important... Read more
Donor-Derived DNA Testing May Reduce Biopsies in Kidney Transplant Monitoring
Kidney transplant recipients require ongoing monitoring for rejection and graft injury, but biopsy-based assessment can be complicated by invasive surveillance procedures and ambiguous findings.... Read moreHematology
view channel
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read moreImmunology
view channel
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read more
COVID-19 and Flu Combo Test Launches With FDA Clearance
Overlapping symptoms of COVID-19 and influenza can create diagnostic uncertainty, particularly in urgent and point-of-care settings. Rapid differentiation from a single specimen can streamline triage and... Read morePathology
view channel
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read more
AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
Cancer screening programs cover only certain cancers and often rely on broad eligibility criteria, limiting individualized risk assessment across multiple cancer types. Routine health data, including blood... Read moreIndustry
view channel
Collaboration Brings Tumor-Informed MRD Monitoring to Breast Cancer Care in Abu Dhabi
For many patients, cancer treatment does not eliminate the risk of recurrence, which may occur months or years later and become harder to treat after spreading. Recurrence is often detected only after... Read more







